Skin and muscle inflammation companiesThese include AstraZeneca, Bristol-Myers Squibb, Pfizer, Octapharma AG, Corbus Pharmaceuticals, Ermium Therapeutics, Kezar Life Sciences, Neovacs, Horizon Therapeutics, Priovant Therapeutics, CSL Behring, Alexion, Idera Pharmaceuticals, Galapagos NV, EMD Serono, Japan Blood Products Organization, Mallinckrodt, Genentech, Astellas Pharma, Biogen, and several others.

Overview of the Dermatomyositis Treatment Market

(Albany, USA) – DelveInsight 「Dermatomyositis Market Insights, Epidemiology, and Market Forecast – 2034” The report provides comprehensive insights into the disease landscape, historical and projected epidemiological trends, and evolving market scenario across the US, EU4 (Germany, Spain, Italy, France), UK, and Japan.

The report provides a detailed look at the current treatment algorithms, emerging treatment options, and market shares of individual drugs, and forecasts the market size from 2020 to 2034. Key dynamics such as market drivers, barriers, and unmet clinical needs are thoroughly analyzed to present viable business opportunities.

📌 For more details on drug-taking trends, treatment prospects, and epidemiological insights, access: Dermatomyositis Market Forecast

Key Insights from the Dermatomyositis Market Report

• The dermatomyositis market is estimated at$230 million in 2023, and is expected to grow significantly at a notable CAGR until 2034.
  
  
• in February 2025, NovelMed TherapeuticsFDA approval of Phase II trialUse of ruxopruvert (NM8074) for dermatomyositis.
  
  
• in December 2024, RemainsULSC ProgramReceivedOrphan Drug Designation (ODD)It is FDA approved for both polymyositis and dermatomyositis.
  
  
• in September 2024, Cartesian Therapy"Descartes-08ReceivedRare pediatric disease designationIn the case of juvenile dermatomyositis (JDM).
  
  
• Privant TherapeuticsFinishedPhase 3 VALOR Trial Registration for BrepositinibIt will take place in July 2024, with 241 participants registered across 90 locations around the world.
  
  
• In 2023,Prevalence in the United Stateswas the highest40-59 years old(approximately 14,600 cases), followed by 60 to 79 (up to 13,000), 18 to 39 (up to 5,000), 0 to 17 (up to 4,000), and 80 or more (up to 1,500).
  
  
• GermanyLeading the EU5 market (approximately US$15 million), followed byUnited Kingdom (approximately US$13 million)In 2023.SpainThe share was minimal (approximately US$9 million).
  
  
• the other side 7MM, was diagnosedPopular casesIt was approximately71,000 people in 2023, and is predicted to increase steadily through 2034.
  
  
• of WeThe number of diagnosed cases is the highest (approximately 38,000), followed byJapan (~12,000)。
  
  
• Dermatomyositis is more common in the following areas:More women than men (2:1 ratio)。
  
  

Overview of Dermatomyositis

Dermatomyositis is a rare inflammatory myopathy with characteristic symptoms of proximal muscle weakness and distinctive skin manifestations such as heliotrope rash and Gottron papules. This autoimmune disease can impair mobility and may be associated with underlying malignancies in some cases.

Diagnosis usually includes muscle biopsy, EMG, MRI, elevated muscle enzymes, and specific autoantibody testing (e.g., anti-Mi-2, anti-NXP2, anti-TIF1-γ). Treatment strategies include corticosteroids, immunosuppressants, and biologics, complemented by physical and supportive care.

📥 Download a free sample: Dermatomyositis Treatment Market Report

Epidemiology of dermatomyositis

The epidemiology section assesses historical and projected trends over the 7MM from 2020 to 2034. Detailed insights are provided on prevalence, severity disaggregation, gender-specific data, and diagnosed case analysis for both episodic and chronic forms.

Epidemiological breakdown:

• Total prevalence
  
  
• Severity-based prevalence
  
  
• Gender distribution
  
  
• Diagnosed episodic and chronic cases
  
  

📈 Discover what's driving these trends: Epidemiological prediction of dermatomyositis

Dermatomyositis Drug Pipeline and Uptake

This section tracks the launch timelines, adoption rates, and sales forecasts of recently approved and upcoming therapies. Comparative analysis identifies the therapies that are gaining rapid adoption and are gaining traction in the market.

The pipeline section provides insights into key late- and early-stage assets, ongoing collaborations, regulatory milestones and licensing agreements.

Notable Dermatomyositis Treatments and Sponsors

• Brepositinib – Privant Therapeutics
  
  
• Renabasm – Corvas Pharmaceuticals
  
  
• Hizentra – CSL Behring
  
  
• Ravulizumab – Alexion
  
  
• IMO-8400 – Idera Pharmaceutical
  
  
• GLPG3667 – Galapagos Nevada
  
  
• M5049 – EMD Serono
  
  
• PF-06823859 – Pfizer
  
  
• 8 matches – Octapharma
  
  
• KZR-616 – Kezar Life Sciences
  
  
• GB-0998 – Japan Blood Products Organization
  
  
• HP Actor Gel/ACTH Gel – Mallinckrodt
  
  
• Tocilizumab – Genentech
  
  
• Tacrolimus – Astellas Pharma
  
  
• Rituximab – Biogen
  
  

🔍 Discover key medicines in development: Dermatomyositis Drug Market

Market Strengths and Opportunities

Strengths:

• Advances in understanding pathogenesis have paved the way for targetingC5 complement, IFNβ1, FcRn, etc.
  
  
• Currently, clinical guidelines provide a structured approach for both adult and adolescent DM.
  
  

opportunity:

• Early prognostic markersEnabling timely intervention can change outcomes.
  
  
• There is plenty of room for unmet need and limited treatment options.First-in-class and best-in-class innovation。
  
  

Report Scope

• Forecast Period: 2020–2034
  
  
• Target area: US, EU5 (Germany, France, Italy, Spain, UK), Japan
  
  
• Key players: AstraZeneca, BMS, Pfizer, Octapharma, Corvus, CSL Behring, Alexion, Genentech, Biogen, etc.
  
  
• Primary treatment: Brepositinib, Lenavasum, KZR-616, Ratulizumab, Octagam, etc.
  
  
• Types of Analysis: Competitive environment, SWOT, PESTLE, BCG matrix, market entry strategy
  
  
• coverageMarketed and pipeline drugs, KOL insights, pricing and reimbursement landscape
  
  

📄 table of contents

1. introduction
   
   
2. executive summary
   
   
3. SWOT Analysis
   
   
4. Patient Share Overview
   
   
5. Market Overview
   
   
6. Background of the disease
   
   
7. Epidemiological trends
   
   
8. Country epidemiology
   
   
9. Current treatment status
   
   
10. Unmet needs
    
    
11. New Treatments
    
    
12. Market Forecast
    
    
13. Country Market Insights
    
    
14. Access and Refunds
    
    
15. Market Drivers
    
    
16. Market Barriers
    
    
17. appendix
    
    
18. Methodology
    
    
19. About DelveInsight
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading healthcare business consulting and market research firm dedicated to providing in-depth analysis and strategic insights to pharmaceutical and biotechnology companies globally.